Abstract: A fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.

Abstract: A GDF15 fusion protein and a method for treating obesity using same. The fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has an amino acid substitution at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form a homodimer. By means of fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physical and chemical properties and recombinant expression level, has an in vitro activity comparable to or better than that of a natural GDF15 molecule, and has a significantly prolonged in vivo cyclic half-life, which may support the dosing frequency once every two weeks or even once a month.

Abstract: GDF15 fusion proteins and uses thereof, the fusion protein includes an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.

Abstract: An antibody or an antigen-binding fragment thereof is capable of specifically recognizing TrkA and uses thereof. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity with it: heavy chain variable region CDR sequences: SEQ ID NO: 1˜27, light chain variable region CDR sequences: SEQ IN NO: 28˜54. The above antibody can specifically targeted-bind to the TrkA receptor and block the binding of NGF to TrkA.